Anavex Life Sciences Corp (AVXL)

[falconer66a]

The seven dropouts issue.

As far as I can determine, there is no information telling why seven trial participants dropped out. There is no good reason to believe these drop-outs occurred because of adverse events, bad side effects, from Anavex 2-73.

People drop out of clinical trials for many reasons, unrelated to and unaffected by the drug being investigated in the trial. Remember, almost all Alzheimer's patients are elderly, open to any number of geriatric health conditions and problems, and of which (unrelated to Anavex 2-73) could prompt the decision to drop out of the trial.

In fact, I would think it to be required to report any trial drug-induced drop outs, drop-outs caused by trial drug-induced adverse events. I've seen no such reports. I presume, therefore, that the seven drop outs were for other reasons, not directly caused by Anavex 2-73. Those seven individuals do not, as I understand it, taint or question the trial's remarkably favorable low adverse incident rate. As the published trial data show, Anavex 2-73 is without any disqualifying adverse events. Side effects, when present, are relatively mild (headache, et al.) and do not complicate the drug's usage in any way.

The published data are clear. Anavex 2-73 is utterly safe when prescribed in the dosage ranges of the P1/P2 Australian clinical trial.